Clinical Research, Pharma & Healthcare FinancingDisitamab Vedotin Phase 3 Trial Hits PFS & OS EndpointsPR NewswireMay 12, 2025May 13, 2025 by PR NewswireMay 12, 2025May 13, 2025099 RemeGen Co., Ltd. announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希®), the first domestically approved antibody-drug...
